Finnish Study Links Oral Anticoagulation to Lower Stroke Risk
Oral anticoagulation therapy following an intracranial hemorrhage in patients diagnosed with atrial fibrillation associates with a lower risk of subsequent ischemic stroke and death, according to a nationwide Finnish cohort study published October 21, 2026, in Neurology.
- Direct oral anticoagulant use links to reduced risks of ischemic stroke and death without increasing intracranial bleeding rates compared to non-treatment.
- Warfarin use associates with lower stroke and mortality risks but correlates with an elevated hazard for recurrent intracranial hemorrhage.
- Clinical treatment decisions remain complex, requiring individualized assessments regarding patient bleeding risks and stroke prevention strategies.
Finnish Cohort Evaluation of Anticoagulation Strategies
The nationwide study tracked 1,502 adult patients diagnosed with first-ever atrial fibrillation between 2010 and 2017 who experienced an intracranial bleeding event at least 120 days prior to their arrhythmia diagnosis and maintained a CHA2DS2-VA score of 2 or higher. Researchers categorized participants by their antithrombotic strategy 90 days after diagnosis: 15% received direct oral anticoagulants, 29% received warfarin, and 56% received no oral anticoagulation. Follow-up monitoring continued for up to two years, noting that 41% of the cohort possessed a history solely of traumatic intracranial bleeding while 59% presented with nontraumatic events.
Direct Oral Anticoagulants Lower Ischemic Stroke and Death Risks
At the two-year mark, adjusted absolute risks for ischemic stroke reached 1.9% for direct oral anticoagulant users, 3.1% for warfarin users, and 6.1% for patients receiving no anticoagulation. Corresponding risks for recurrent intracranial hemorrhage stood at 2.7%, 6.5%, and 2.9% across the respective cohorts, while mortality from other causes registered at 10.1%, 15.6%, and 24.6%. When compared to untreated patients, direct oral anticoagulant users demonstrated lower hazards for ischemic stroke and death, yet showed no statistically significant difference in intracranial bleeding risk. Warfarin users similarly exhibited reduced ischemic stroke and mortality hazards, but faced a heightened risk for recurrent brain bleeds.
Stratification by Therapeutic Range and Expert Assessment
Investigators further stratified warfarin users by time in the therapeutic range, noting that 48.12% of the 374 evaluated patients achieved a time in therapeutic range of 70% or greater. Patients achieving this threshold experienced significantly lower risks for ischemic stroke and death, whereas those failing to reach 70% saw these protective benefits attenuated. Paula Tiili of Helsinki University Hospital stated in a press release that the findings help clinicians make more individualized treatment decisions, though she emphasized that additional research is necessary to identify which patients benefit most and who continues to face elevated bleeding vulnerabilities.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.